{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:36:17Z","timestamp":1781195777542,"version":"3.54.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002210"],"award-info":[{"award-number":["82002210"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Antinuclear antibodies (ANAs) have been reported to be associated with cancers. However, the role of different ANA patterns in cancers is poorly understood, especially in leukemia. This study aimed to investigate the association between ANA patterns and the outcome of leukemia in a retrospective cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 429 adult patients initially diagnosed with leukemia at Henan Provincial People\u2019s Hospital from January 2014 to December 2018 were included in this study, including information on patients without positive ANAs at the time of initial diagnosis, preexisting autoimmune diseases, infectious diseases, etc. The data were retrieved up to December 2020. The final sample included 196 adult patients. The risk of death outcome according to ANA patterns was estimated using multivariable Cox proportional hazards models and the overall survival for ANA patterns was analyzed using Kaplan\u2013Meier curve.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>ANAs with a nucleolar pattern <jats:italic>versus<\/jats:italic> negative ANA were associated with a two-fold increased risk of death outcome in leukemia, independent of sex, age, leukemia immunophenotype, cytogenetic abnormality, treatment, and blood transfusion. Further analysis revealed that the association was more significant in elder patients (\u226560 years) and patients treated with tyrosine kinase inhibitor or chemotherapy (P for interaction = 0.042 and 0.010). Notably, the patients with a nucleolar pattern had shorter survival than the patients with a non-nucleolar pattern or without ANA (<jats:italic>p<\/jats:italic> &amp;lt; 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ANAs with a nucleolar pattern are a significant predictor of poor prognosis, providing clues for prognostic assessment in patients with leukemia.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.631038","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T06:46:22Z","timestamp":1614321982000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Antinuclear Antibodies With a Nucleolar Pattern Are Associated With a Significant Reduction in the Overall Survival of Patients With Leukemia: A Retrospective Cohort Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Rong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.0108","article-title":"Identification and Validation of Novel Serum Autoantibody Biomarkers for Early Detection of Colorectal Cancer and Advanced Adenoma","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.01.007","article-title":"Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer","volume":"346","author":"Chen","year":"2014","journal-title":"Cancer Lett"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.05.002","article-title":"Antinuclear antibodies and cancer: A literature review","volume":"127","author":"Vlagea","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053007","article-title":"Prognostic significance of autoimmunity during treatment of melanoma with interferon","volume":"354","author":"Gogas","year":"2006","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.imlet.2019.03.002","article-title":"Antinuclear antibodies in patients with cervical lesions and invasive cervical cancer","volume":"208","author":"Skare","year":"2019","journal-title":"Immunol Lett"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13136","article-title":"Anti-nuclear antibodies in patients with breast cancer","volume":"193","author":"Nisihara","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1186\/s12885-015-1385-8","article-title":"Autoantibodies in breast cancer sera are not epiphenomena and may participate in carcinogenesis","volume":"15","author":"Madrid","year":"2015","journal-title":"BMC Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejca.2017.12.025","article-title":"The future of blood-based biomarkers for the early detection of breast cancer","volume":"92","author":"Loke","year":"2018","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.10.012","article-title":"The roles and applications of autoantibodies in progression, diagnosis, treatment and prognosis of human malignant tumours","volume":"16","author":"Wu","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-0932","article-title":"Autoantibodies to Annexin XI-A and Other Autoantigens in the Diagnosis of Breast Cancer","volume":"64","author":"Fernandez-Madrid","year":"2004","journal-title":"Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm007","article-title":"Autoantibodies in breast cancer: their use as an aid to early diagnosis","volume":"18","author":"Chapman","year":"2007","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1588084","DOI":"10.1080\/2162402X.2019.1588084","article-title":"Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival","volume":"8","author":"Watad","year":"2019","journal-title":"Oncoimmunology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214436","article-title":"Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective","volume":"78","author":"Damoiseaux","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00165","article-title":"Antinuclear Antibodies With a Homogeneous and Speckled Immunofluorescence Pattern Are Associated With Lack of Cancer While Those With a Nucleolar Pattern With the Presence of Cancer","volume":"7","author":"Gauderon","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s100670050029","article-title":"Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis","volume":"19","author":"Higuchi","year":"2000","journal-title":"Clin Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2016.10.002","article-title":"[Chinese guidelines for diagnosis and treatment of acute lymphoblastic leukemia(2016)]","volume":"37","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2017.03.001","article-title":"[Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2017)]","volume":"38","year":"2017","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2018.03.002","article-title":"[Chinese guidelines for diagnosis and treatment of acute promyelocytic leukemia (2018)]","volume":"39","year":"2018","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2016.08.001","article-title":"[The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2016 edition)]","volume":"37","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2018.05.001","article-title":"[The guidelines for diagnosis and treatment of chronic lymphocytic leukemia\/small lymphocytic lymphoma in China (2018 edition)]","volume":"39","year":"2018","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2014.08.029","article-title":"[The consensus of allogeneic hematopoietic transplantation for hematological diseases in China (2014)\u2013indication, conditioning regimen and donor selection]","volume":"35","year":"2014","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv104","article-title":"Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses","volume":"26","author":"Mitchell","year":"2015","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316688783","article-title":"Can killers be saviors","volume":"26","author":"Singh","year":"2017","journal-title":"Lupus"},{"key":"B25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s12032-020-01440-3","article-title":"Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients","volume":"37","author":"Morimoto","year":"2020","journal-title":"Med Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.lungcan.2019.01.014","article-title":"Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies","volume":"130","author":"Yoneshima","year":"2019","journal-title":"Lung Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e30997","DOI":"10.1371\/journal.pone.0030997","article-title":"Circulating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survival","volume":"7","author":"Heegaard","year":"2012","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of Autoantibody-Induced Pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2020.101394","article-title":"Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention","volume":"47","author":"Jacqueline","year":"2020","journal-title":"Semin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.8.5084","article-title":"Monoclonal pathogenic antibodies to the thyroid-stimulating hormone receptor in Graves\u2019 disease with potent thyroid-stimulating activity but differential blocking activity activate multiple signaling pathways","volume":"176","author":"Gilbert","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.autrev.2013.03.014","article-title":"Prevalence and clinical significance of rare antinuclear antibody patterns","volume":"12","author":"Vermeersch","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B32","article-title":"Antinuclear, antinucleolar, and anticytoplasmic antibodies in patients with malignant melanoma","volume":"43","author":"Thomas","year":"1983","journal-title":"Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.01.017","article-title":"Autoantibody Production in Cancer\u2013The Humoral Immune Response toward Autologous Antigens in Cancer Patients","volume":"15","author":"Zaenker","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B34","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrc1885","article-title":"Nucleophosmin and cancer","volume":"6","author":"Grisendi","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.biochi.2015.03.023","article-title":"The roles of nucleolin subcellular localization in cancer","volume":"113","author":"Berger","year":"2015","journal-title":"Biochimie"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61788","article-title":"Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy","volume":"122","author":"Sauer","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.B1900205","article-title":"Potential value of autoantibodies as biomarkers of chronic graft-versus-host disease after allogeneic stem cell transplantation","volume":"20","author":"Hao","year":"2019","journal-title":"J Zhejiang Univ Sci B"},{"key":"B38","article-title":"Anti-nuclear antibody positivity in multi-transfused thalassemia major","volume":"29","author":"Agarwal","year":"1992","journal-title":"Indian Pediatr"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1995.35395184273.x","article-title":"Changes in peripheral blood CD5 (Bla) B-cell populations and autoantibodies following blood transfusion","volume":"35","author":"Paglieroni","year":"1995","journal-title":"Transfusion"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2006.10.002","article-title":"Antinuclear antibodies in the oldest-old women and men","volume":"27","author":"Nilsson","year":"2006","journal-title":"J Autoimmun"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.631038\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T06:46:29Z","timestamp":1614321989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.631038\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":40,"alternative-id":["10.3389\/fonc.2021.631038"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.631038","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"article-number":"631038"}}